Aptevo Therapeutics Files 8-K on Agreements and Equity Sales
Ticker: APVO · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
Related Tickers: APVO
TL;DR
APVO filed an 8-K: material definitive agreement, unregistered equity sales, and financials. Big moves happening.
AI Summary
On June 16, 2025, Aptevo Therapeutics Inc. filed an 8-K report detailing an entry into a material definitive agreement and unregistered sales of equity securities. The filing also includes financial statements and exhibits, with the report being filed as of June 17, 2025.
Why It Matters
This filing indicates significant corporate actions by Aptevo Therapeutics, including new agreements and the issuance of equity, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 001-37746 — SEC File Number (Identifies the specific SEC filing for Aptevo Therapeutics Inc.)
- 81-1567056 — IRS Employer Identification No. (Tax identification number for Aptevo Therapeutics Inc.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- June 16, 2025 (date) — Date of earliest event reported
- June 17, 2025 (date) — Filing date
- 206-838-0500 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Aptevo Therapeutics?
The 8-K filing indicates an entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold unregistered?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not disclosed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 16, 2025.
What is the principal executive office address for Aptevo Therapeutics?
The principal executive offices of Aptevo Therapeutics are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
What is the SIC code for Aptevo Therapeutics?
The Standard Industrial Classification (SIC) code for Aptevo Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Aptevo Therapeutics Inc. (APVO).